369 related articles for article (PubMed ID: 33076714)
1. Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.
Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2020 Nov; 13(11):1189-1199. PubMed ID: 33076714
[TBL] [Abstract][Full Text] [Related]
2. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
Sankar K; Stein BL
J Natl Compr Canc Netw; 2018 Dec; 16(12):1539-1545. PubMed ID: 30545998
[TBL] [Abstract][Full Text] [Related]
3. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
6. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
8. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
9. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
Vannucchi AM; Guglielmelli P
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):480-488. PubMed ID: 29222296
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
13. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi R; Di Gennaro L
Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
[No Abstract] [Full Text] [Related]
14. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
15. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
16. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and management of essential thrombocythemia.
Beer PA; Green AR
Hematology Am Soc Hematol Educ Program; 2009; ():621-8. PubMed ID: 20008247
[TBL] [Abstract][Full Text] [Related]
18. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Bose P; Verstovsek S
Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
[No Abstract] [Full Text] [Related]
20. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
